In short
This article summarizes several clinical trials investigating the use of MPS-103, a component of the OSE2101 (Tedopi) cancer vaccine, in treating various advanced cancers. OSE2101 is being studied alone and in combination with other therapies for non-small cell lung cancer, ovarian cancer, and pancreatic cancer. The trials aim to evaluate the safety and efficacy of OSE2101 in improving outcomes for patients with these difficult-to-treat advanced cancers.
What is MPS-103?
MPS-103 is one of the active substances in an investigational cancer vaccine called TEDOPI. TEDOPI is being developed by OSE Immunotherapeutics as a potential new treatment for certain types of cancer. It contains 10 synthetically manufactured peptides (small protein fragments), including MPS-103.
How Does MPS-103 Work?
As part of the TEDOPI vaccine, MPS-103 is designed to stimulate the immune system to recognize and attack cancer cells. The vaccine works by presenting specific protein fragments that are found on cancer cells to the immune system. This helps train the immune system to identify these cancer-associated proteins as foreign and mount an attack against cells displaying them.
What Conditions is MPS-103 Being Studied For?
TEDOPI, which contains MPS-103, is currently being investigated for the treatment of several types of cancer, including:
- Non-small cell lung cancer (NSCLC): This is a type of lung cancer that is being studied in patients whose cancer has progressed after previous immunotherapy treatment.
- Ovarian cancer: TEDOPI is being evaluated as a maintenance treatment for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy.
- Pancreatic cancer: The vaccine is being studied in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Current Clinical Trials
Several clinical trials are currently underway to evaluate the safety and effectiveness of TEDOPI (containing MPS-103) in different cancer types:
- ARTEMIA study: This is a phase 3 trial comparing TEDOPI to docetaxel (a chemotherapy drug) in patients with advanced non-small cell lung cancer who have developed resistance to previous immunotherapy.
- TEDOVA study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab (another immunotherapy drug) as a maintenance treatment for patients with recurrent ovarian cancer.
- TEDOPAM study: A phase 2 trial investigating TEDOPI in combination with chemotherapy for patients with advanced pancreatic cancer.
Potential Benefits and Side Effects
As TEDOPI (including MPS-103) is still in clinical trials, its full benefits and risks are not yet fully known. However, researchers hope that it may provide a new treatment option for patients with certain types of cancer, particularly those who have not responded well to other treatments.
Potential benefits being studied include:
- Improved overall survival
- Longer progression-free survival (time without cancer growing or spreading)
- Better quality of life compared to some existing treatments
As with any medical treatment, there may be side effects. Common side effects of cancer vaccines can include injection site reactions, fatigue, and flu-like symptoms. More serious side effects are possible but less common. The ongoing clinical trials are carefully monitoring patients for any adverse effects.
It's important to note that as an investigational treatment, TEDOPI (containing MPS-103) is not yet approved for general use. Patients interested in this treatment should speak with their healthcare provider about the possibility of participating in clinical trials.